CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · Real-Time Price · USD
6.87
-0.44 (-6.05%)
At close: Jun 16, 2025, 4:00 PM
11.96
+5.09 (74.14%)
Pre-market: Jun 17, 2025, 7:18 AM EDT

Company Description

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.

Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors.

The company was incorporated in 2021 and is based in South San Francisco, California.

CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings logo
Country United States
Founded 2017
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Christopher Ehrlich

Contact Details

Address:
201 Haskins Way, Suite 230
South San Francisco, California 94080
United States
Phone (650) 407-2376
Website cero.bio

Stock Details

Ticker Symbol CERO
Exchange NASDAQ
Stock Type Common Stock
Share Class Class A Shares
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001870404
ISIN Number US71902K3032
Employer ID 87-1088814
SIC Code 2836

Key Executives

Name Position
Christopher B. Ehrlich M.B.A. Chief Executive Officer and Chair
Andrew Albert Kucharchuk M.B.A. Chief Financial Officer
Dr. Kristen Pierce Ph.D. Chief Development Officer
Dr. Lawrence Corey M.D. Co-founder and Head of Scientific Advisory Board

Latest SEC Filings

Date Type Title
Jun 16, 2025 424B3 Prospectus
Jun 13, 2025 8-K Current Report
Jun 11, 2025 8-K Current Report
Jun 6, 2025 424B3 Prospectus
Jun 6, 2025 8-K Current Report
Jun 2, 2025 8-K Current Report
May 29, 2025 EFFECT Notice of Effectiveness
May 29, 2025 8-K Current Report
May 27, 2025 POS AM Post-Effective amendments for registration statement
May 15, 2025 10-Q Quarterly Report